Idarucizumab: An anticoagulant reversal agent for dabigatran

Anthony F. T. Brown, Harshal Nandurkar

Research output: Contribution to journalReview ArticleOtherpeer-review

Abstract

Idarucizumab is a specific reversal agent for the novel oral anticoagulant (NOAC) dabigatran. Idarucizumab is indicated when rapid, complete and sustained reversal of dabigatran’s anticoagulant effect is needed, such as when the patient requires emergency surgery or an urgent procedure, or has life-threatening or uncontrolled bleeding.
Original languageEnglish
Pages (from-to)63-65
Number of pages3
JournalMedicine Today
Volume17
Issue number11
Publication statusPublished - 1 Nov 2016

Cite this

Brown, Anthony F. T. ; Nandurkar, Harshal. / Idarucizumab : An anticoagulant reversal agent for dabigatran. In: Medicine Today. 2016 ; Vol. 17, No. 11. pp. 63-65.
@article{f8828e3d0e9049a788154b663a91758b,
title = "Idarucizumab: An anticoagulant reversal agent for dabigatran",
abstract = "Idarucizumab is a specific reversal agent for the novel oral anticoagulant (NOAC) dabigatran. Idarucizumab is indicated when rapid, complete and sustained reversal of dabigatran’s anticoagulant effect is needed, such as when the patient requires emergency surgery or an urgent procedure, or has life-threatening or uncontrolled bleeding.",
author = "Brown, {Anthony F. T.} and Harshal Nandurkar",
year = "2016",
month = "11",
day = "1",
language = "English",
volume = "17",
pages = "63--65",
journal = "Medicine Today",
issn = "1443-430X",
publisher = "Medicine Today",
number = "11",

}

Idarucizumab : An anticoagulant reversal agent for dabigatran. / Brown, Anthony F. T.; Nandurkar, Harshal.

In: Medicine Today, Vol. 17, No. 11, 01.11.2016, p. 63-65.

Research output: Contribution to journalReview ArticleOtherpeer-review

TY - JOUR

T1 - Idarucizumab

T2 - An anticoagulant reversal agent for dabigatran

AU - Brown, Anthony F. T.

AU - Nandurkar, Harshal

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Idarucizumab is a specific reversal agent for the novel oral anticoagulant (NOAC) dabigatran. Idarucizumab is indicated when rapid, complete and sustained reversal of dabigatran’s anticoagulant effect is needed, such as when the patient requires emergency surgery or an urgent procedure, or has life-threatening or uncontrolled bleeding.

AB - Idarucizumab is a specific reversal agent for the novel oral anticoagulant (NOAC) dabigatran. Idarucizumab is indicated when rapid, complete and sustained reversal of dabigatran’s anticoagulant effect is needed, such as when the patient requires emergency surgery or an urgent procedure, or has life-threatening or uncontrolled bleeding.

UR - http://www.scopus.com/inward/record.url?scp=84997703700&partnerID=8YFLogxK

UR - http://medicinetoday.com.au/2016/november/regular-series/idarucizumab-anticoagulant-reversal-agent-dabigatran

M3 - Review Article

VL - 17

SP - 63

EP - 65

JO - Medicine Today

JF - Medicine Today

SN - 1443-430X

IS - 11

ER -